SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2017

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 16. SUBSEQUENT EVENTS

On November 7, 2017, the Company entered into an agreement with Slán Medicinal Holdings Limited (Slán) under which it (i) acquired from Slán certain rights to market the specialty drug, cosyntropin (Synthetic ACTH Depot) in the United States and (ii) divested to Slán all of its rights to Lazanda® (fentanyl) nasal spray CII.

On November 8, 2017, the Company, in accordance with the terms of the Senior Notes, prepaid $10 million of the remaining $375 million principal amount thereunder. In addition, the Company also paid a $0.4 million prepayment fee and recorded an expense for related unamortized balances of debt discount and debt issuance costs in November 2017.